Introduction
============

Accurate prognostication is a core aspect of oncology and palliative care.[@b1-pcrt-9-2015-007],[@b2-pcrt-9-2015-007] At a time of increasing availability of new and expensive cancer treatments with variable survival benefits, accurate prognostication is important in selecting beneficial treatments and avoiding treatments that may not be in the best interest of the patient.[@b3-pcrt-9-2015-007]--[@b5-pcrt-9-2015-007] Timely diagnosis of the end stage of life, coupled with effective communication, is an integral part of palliative management and empowers the patient and their caregivers to become active, effective participants in clinical decision-making and patient care.[@b6-pcrt-9-2015-007]

However, accurate prognostication has proved to be challenging and the tendency for clinicians to be inaccurate and overestimate survival is well documented.[@b7-pcrt-9-2015-007]--[@b9-pcrt-9-2015-007] Barriers to prognostication include suboptimal training of clinicians in this clinical skill, with much greater focus on diagnostic and therapeutic skills,[@b1-pcrt-9-2015-007],[@b10-pcrt-9-2015-007] reluctance among clinicians to prognosticate,[@b10-pcrt-9-2015-007] and a lack of accurate prognostic tools to guide clinicians who are caring for patients with advanced illness.[@b10-pcrt-9-2015-007],[@b11-pcrt-9-2015-007] In recent years, several prognostic tools have been developed to improve prognostication in palliative care patients.[@b12-pcrt-9-2015-007]--[@b16-pcrt-9-2015-007] The PaP score is one of two validated prognostic tools for use in patients with advanced cancer that was identified by the steering committee of the Research Network of the European Association for Palliative Care.[@b2-pcrt-9-2015-007]

The PaP score relies heavily upon a clinical prediction of survival (CPS), which is commonly determined by a single clinician. The CPS has the highest partial weight among the components of the PaP score. It is measured in 1- to 2-week intervals up to 12 weeks, after which all estimates are grouped as \>12 weeks. Although the CPS tends to correlate with survival,[@b17-pcrt-9-2015-007] it is twice as likely to be overoptimistic than over-pessimistic and to overestimate the length of actual survival by a factor of between 3 and 5.[@b2-pcrt-9-2015-007],[@b17-pcrt-9-2015-007] It appears that the use of CPS with validated tools affords the greatest accuracy in predicting survival.[@b18-pcrt-9-2015-007] In addition, early data suggest that a multidisciplinary team prediction of survival (MTPS) is better than the prediction of a doctor or nurse clinician alone.[@b19-pcrt-9-2015-007]

In settings such as the outpatient palliative care clinic in a cancer center, where patients tend to have longer survival,[@b20-pcrt-9-2015-007] the application of PaP has not been well studied. One prospective study which looked at the survival of 250 Brazilian female outpatients with advanced malignancies found that the PaP score subdivided the study population into three groups according to their survival, consistent with the three groups identified in the validation and subsequent studies of PaP.[@b21-pcrt-9-2015-007] Given that palliative care is increasingly integrated into the outpatient setting in cancer centers, it is important to have prognostic tools that are useful for this population of patients.[@b22-pcrt-9-2015-007]

In our center, we calculate the PaP score using the MTPS which is agreed by the palliative care team at a weekly multidisciplinary team meeting. This score is entered into the PaP score with the other five factors and is weighted in the same way as the CPS would have been weighted. The purpose of this study was to describe and analyze this multidisciplinary approach to prognostication in palliative care patients with cancer.

Methods
=======

Study setting and participants
------------------------------

This retrospective study was conducted at the Peter MacCallum Cancer Centre by the Department of Pain and Palliative Care (DPPC) consultative service. Patients are referred to the DPPC by oncologists within multidisciplinary tumor streams for assessment and management of symptoms associated with cancer and its treatment, care coordination and planning, and end-of-life care. Referred patients may be first seen in an inpatient setting of the cancer center, when under the primary care of their oncologist, or while attending outpatient clinics for oncological management and review. The DPPC conduct twice-daily palliative care outpatient clinics, termed Rapid Response Clinics, which enable the same-day review of urgent referrals concurrent with their oncology review, as well as booked reviews.

On first review, all patients undergo comprehensive assessment, by either a palliative care doctor or nurse practitioner, which includes completion of a suite of validated assessment tools, including the Edmonton Classification Scale for Cancer Pain, Palliative Prognostic (PaP) Score, and a pain chart. Other data include demographics such as the date of birth, date of cancer diagnosis, referring tumor stream, performance status measures (Karnofsky Performance Status \[KPS\]), genogram with a focus on assessment of children and bereavement risk, and pathology parameters (total white blood cell \[WBC\] and lymphocyte count). The prediction of survival is reached by consensus within the weekly multidisciplinary team (MDT) meeting, with most input from medical and nursing team members. The palliative care MDT at that meeting consists of palliative care specialist doctors, palliative care nurses, a social worker, a pharmacist, and a pastoral care worker. These data are recorded in the DPPC database.

Study inclusion was limited to patients with a solid malignancy who had a first contact by the palliative care team between 1 January 2010 and 31 December 2011 and had deceased before 1 June 2012, when the data were extracted. Patients with an incomplete data set or with primary renal or hematological malignancy were excluded as in the original PaP score study due to possible effects on blood values.[@b15-pcrt-9-2015-007] Overall survival was defined as time from first encounter by DPPC to death from any cause. If a patient had multiple contacts with the palliative care team, only data from the first contact were included for analysis.

Inpatients were defined as patients who had their first contact with the palliative care team during an inpatient hospital admission. Outpatients were nonadmitted patients who had their first contact with the palliative care team when attending an outpatient clinic or attending for same-day treatments such as radiotherapy, chemotherapy, or apheresis.

Ethics approval was obtained from the Human Research and Ethics Committee at the Peter MacCallum Cancer Center, Melbourne (June 2012 No 12/83).

PaP score
---------

The PaP score consists of six prognostic elements, CPS, KPS, anorexia, dyspnea, total WBC count, and lymphocyte percentage. Each element is assigned a weighted partial score, the sum of which ranges from 0 to 17.5, which then classifies patients with advanced solid malignancy into three risk categories predictive of 30-day survival. These are group A (score ≤5.5), probability \>70%; group B (score 5.6--11.0), 30-day survival probability 30%--70%; group C (score ≥11.1), 30-day survival probability \<30%.[@b15-pcrt-9-2015-007],[@b23-pcrt-9-2015-007]

Statistical analysis
--------------------

The prognoses estimated by the MTPS and calculated by MTPS-PaP score were each correlated with actual survival. The data for inpatients and outpatients were analyzed separately in view of the different nature of these two populations.

Differences in patient demographics, disease characteristics, MTPS-PaP score, and MTPS by patient cohort were analyzed by chi-squared tests for categorical variables, *t*-tests for continuous parametric variables, or the Wilcoxon rank-sum test for continuous nonparametric variables. Overall survival was estimated using the nonparametric Kaplan--Meier method. Comparisons of the MTPS-PaP groups and MTPS categories were made using the log-rank test for trend. Cox proportional hazards analysis was used to compute hazard ratios and 95% confidence intervals (CIs) to assess the effect of MTPS-PaP groups and MTPS categories. Spearman rank-order correlation was used to evaluate the association among MTPS-PaP total score, MTPS partial score, and survival time in both inpatient and outpatient cohorts. Spear-man correlation coefficients of \<0.30, 0.30--0.45, 0.45--0.60, and \>0.60 represented none, moderate, substantial, and high correlation, respectively.

To calculate the overestimation factor, each patient was assigned an MTPS using the midvalue from the MTPS interval. Patients who had an MTPS \>12 weeks were excluded from this analysis since the midvalue for this category was undefined. The ratio of the MTPS and actual survival was calculated for each patient and then log transformed as the ratio had strong positively skewed distribution. Geometric means and CIs were used when reporting the overestimation factor.

All *P*-values reported were two sided, without any adjustment for multiple comparisons. Reported CIs are 95%. All statistical analyses were performed using SAS statistical software, version 9.2 (SAS Institute).

Results
=======

The analysis included 644 patients, which was 89.8% of total eligible patients ([Fig. 1](#f1-pcrt-9-2015-007){ref-type="fig"}). Separate analyses were conducted for inpatients (*n* = 421) and outpatients (*n* = 223).

Patient characteristics are described in [Table 1](#t1-pcrt-9-2015-007){ref-type="table"}. The median age of patients was 63.3 years (range 17--94). The most frequent diseases were lung cancer (146, 22.7%), gastrointestinal cancer (132, 20.5%), skin cancers (89, 13.8%), and head and neck cancer (76, 11.8%). In 91.8% of patients, KPS was more than 30. Anorexia was present in 33.9% of cases and dyspnea in 32%. The inpatient and outpatient populations were significantly different in several PaP domains including presence of dyspnea and anorexia and poor performance status and survival, with significantly longer survival in the outpatient population.

Accuracy of PaP groups
----------------------

The MTPS-PaP score subdivided the inpatient cohort into three homogenous risk groups according to survival time ([Fig. 2A](#f2-pcrt-9-2015-007){ref-type="fig"}, log-rank test for trend *P* \< 0.001). The median survival times for inpatients with PaP groups A, B, and C were 10.9 weeks (76 days), 3.4 weeks (24 days), and 0.7 weeks (5 days), respectively, and the 30-day survival probability was 81%, 40%, and 10%, respectively ([Table 2A](#t2A-pcrt-9-2015-007){ref-type="table"}).

Similar to the inpatient cohort, the MTPS-PaP score subdivided the outpatient cohort into three homogenous risk groups with respect to survival time ([Fig. 2B](#f2-pcrt-9-2015-007){ref-type="fig"}, log-rank test for trend *P* \< 0.001). The median survival times for outpatients with PaP groups A and B were 17.3 weeks (121 days) and 5.1 weeks (36 days), respectively, and the 30-day survival probability was 94% and 50%, respectively. The median survival for PaP group C was only 4 days, but the number of patients in PaP group C was too small (*N* = 4) to reliably calculate 30-day survival probability ([Table 2B](#t2B-pcrt-9-2015-007){ref-type="table"}). Median survival time was longer in the outpatient cohort compared to the inpatient cohort in PaP groups A and B.

The accuracy of MTPS
--------------------

MTPS overestimated median survival in both inpatient and outpatient cohorts. The overestimation factor was 1.5 for inpatients and 1.2 for outpatients ([Table 3A, B](#t3A-pcrt-9-2015-007){ref-type="table"}, and [4](#t4-pcrt-9-2015-007){ref-type="table"}; [Fig. 3A, B](#f3-pcrt-9-2015-007){ref-type="fig"}; log-rank test for trend *P* \< 0.001). Survival predictions were more accurate in outpatients compared to inpatients. In addition, survival predictions were more accurate closer to death and, conversely, less accurate further from death.

Comparison of survival prediction by MTPS and the MTPS-PaP score
----------------------------------------------------------------

Both the MTPS-PaP score and MTPS alone demonstrated substantial correlation with actual survival, with the MTPS-PaP score being slightly more correlated. In the inpatient cohort, the Spearman correlation coefficient for the MTPS-PaP score and MTPS was −0.66 and −0.64, respectively ([Table 5](#t5-pcrt-9-2015-007){ref-type="table"}). In the outpatient cohort, the Spearman correlation coefficient for the MTPS-PaP score and MTPS was −0.57 and −0.53, respectively ([Table 5](#t5-pcrt-9-2015-007){ref-type="table"}).

Discussion
==========

In this study, the MTPS-PaP score accurately classified inpatients into three risk groups based on survival. This is consistent with previous studies that have evaluated the PaP score in the inpatient setting.[@b23-pcrt-9-2015-007]--[@b27-pcrt-9-2015-007] Our data also confirmed the well-recognized *horizon effect* for prognostication, whereby survival estimates are more accurate closer to death and, conversely, less accurate further from death.[@b17-pcrt-9-2015-007],[@b28-pcrt-9-2015-007],[@b29-pcrt-9-2015-007]

We further demonstrated that the PaP score is clinically less useful in the palliative care outpatient setting where survival times are generally longer. Our patient distribution was significantly skewed: 75% of the outpatients fell within PaP group A and less than 2% within group C. With evolving models of care that promote the early integration of palliative care, services will be increasingly involved in the care of outpatients in oncology and other illnesses.[@b30-pcrt-9-2015-007]--[@b32-pcrt-9-2015-007] For this group of patients where survival is generally longer, other prognostic factors such as cancer type, comorbidities, and performance status may play a more important role.[@b33-pcrt-9-2015-007],[@b34-pcrt-9-2015-007] Prognostic tools designed specifically for palliative care outpatients may be of greater utility than the PaP score in this setting.[@b20-pcrt-9-2015-007],[@b35-pcrt-9-2015-007]

While still overestimating actual survival, we found MTPS to be more accurate compared to CPS performed by single clinicians and less accurate than MTPS-PaP. This is consistent with the literature, which recommends the use of CPS in combination with other prognostic factors or scores to improve accuracy of predictions.[@b2-pcrt-9-2015-007]

While improving accuracy of prognostication is important, the focus of our MTPS discussion is not so much about achieving finely tuned prognostic accuracy than about assisting the team to focus on assessing the preparedness of the patient, family, and medical team in coordinating and planning end-of-life care and to ensure that the goals of care are aligned with the estimated prognosis and anticipated outcomes. A multidisciplinary approach to prognostication is in keeping with the overall multidisciplinary approach, which is regarded as the standard of care in oncology and palliative care. We recommend its application as a core activity for palliative care services.

Limitations of this study are its retrospective design with its incumbent risk of bias and missing data. In addition, the data are obtained from a single institution only. The MDT structure varied from week to week; however, it always included palliative care doctors and nurses, who played the major role in determining the prognostic estimate.

Further areas for study include understanding how the MDT arrive at consensus when prognosticating and how each team member contributes to this discussion. A comparison of the accuracy of MTPS versus single-clinician estimate of CPS within the PaP score would be of interest. There is a need to develop prognostic tools that are better suited for the palliative care outpatient setting. Finally, the impact of improving our ability to prognosticate upon our clinical decision-making and patient outcomes has yet to be well studied.
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![(**A**) Kaplan--Meier curve for inpatients. (**B**) Kaplan--Meier curve for outpatients.](pcrt-9-2015-007f2){#f2-pcrt-9-2015-007}

![(**A**) MTPS---median survival and Cox regression model by group (inpatients). (**B**) MTPS---median survival and Cox regression model by group (outpatients).](pcrt-9-2015-007f3){#f3-pcrt-9-2015-007}

###### 

Patient characteristics.

                                                                                                  INPATIENT n = 421   OUTPATIENT n = 223   *P*-VALUE
  ----------------------------------------------------------------------------------------------- ------------------- -------------------- -----------
  **Age (years)**                                                                                                                          
  Median (Min-Max)                                                                                64.6 (18.6--93.9)   61.6 (17.2--91.6)    
  **Tumor type**[\*](#tfn1-pcrt-9-2015-007){ref-type="table-fn"}                                                                           
  Bone and Soft Tissue                                                                            29 (6.9%)           39 (17.5%)           \<.0001
  Breast                                                                                          24 (5.7%)           8 (3.6%)             
  Gastrointestinal                                                                                79 (18.8%)          53 (23.8%)           
  Gynecology                                                                                      37 (8.8%)           16 (7.2%)            
  Head and Neck                                                                                   56 (13.3%)          20 (9.0%)            
  Lung                                                                                            108 (25.7%)         38 (17.0%)           0.01
  Melanoma and Skin                                                                               57 (13.5%)          32 (14.3%)           
  Neuro-oncology                                                                                  1 (0.2%)            0 (0.0%)             
  Urology                                                                                         26 (6.2%)           13 (5.8%)            
  Unknown primary                                                                                 4 (1.0%)            4 (1.8%)             
  **PaP group (30 day survival)**[\*\*](#tfn2-pcrt-9-2015-007){ref-type="table-fn"}                                                        
  \>70%                                                                                           188 (44.7%)         173 (77.6%)          \<.0001
  30--70%                                                                                         146 (34.7%)         46 (20.6%)           0.0002
  \<30%                                                                                           87 (20.7%)          4 (1.8%)             \<.0001
  **Dyspnea**                                                                                                                              
  No                                                                                              270 (64.1%)         168 (75.3%)          0.004
  Yes                                                                                             151 (35.9%)         55 (24.7%)           
  **Anorexia**                                                                                                                             
  No                                                                                              261 (62.0%)         165 (74.0%)          0.002
  Yes                                                                                             160 (38.0%)         58 (26.0%)           
  **Karnofsky performance status**                                                                                                         
  ≥30                                                                                             368 (87.4%)         223 (100.0%)         \<0001
  10--20                                                                                          53 (12.6%)          0 (0.0%)             
  **Clinical prediction of survival (weeks)**[\*\*](#tfn2-pcrt-9-2015-007){ref-type="table-fn"}                                            
  \>12                                                                                            148 (35.2%)         139 (62.3%)          \<.0001
  11--12                                                                                          32 (7.6%)           22 (9.9%)            
  7--10                                                                                           62 (14.7%)          31 (13.9%)           
  5--6                                                                                            44 (10.5%)          13 (5.8%)            
  3--4                                                                                            62 (14.7%)          13 (5.8%)            0.0008
  1--2                                                                                            73 (17.3%)          5 (2.2%)             \<.0001

**Notes:**

Chi-squared test for overall group difference, *P* = 0.001.

Chi-squared test for overall group difference, *P* \< 0.0001.

###### 

Inpatients---median survival and survival probability.

  PaP GROUP           n (%)         MEDIAN SURVIVAL WEEKS (95% CI)   30-DAY SURVIVAL PROBABILITY (95% CI)   HR (95% CI)[\*](#tfn3-pcrt-9-2015-007){ref-type="table-fn"}
  ------------------- ------------- -------------------------------- -------------------------------------- -------------------------------------------------------------
  Group A (\>70%)     188 (44.7%)   10.9 (9.1--12.1)                 81% (76--87%)                          1.00 (reference)
  Group B (30--70%)   146 (34.7%)   3.4 (3.0--4.1)                   40% (32--48%)                          2.16 (1.73--2.70)
  Group C (\<30%)     87 (20.7%)    0.7 (0.6--1.0)                   10% (39--17%)                          8.48 (6.32--11.4)

**Notes:**

Model statistics: Likelihood ratio test *χ*^2^~2~ = 177.8; AIC = 4087.1; Harrell *c*-index = 0.709 (standard error 0.015); *D*-index = 4.16; *R*^2^~D~ = 0.805.

###### 

Outpatients---median survival and survival probability.

  PaP GROUP           n (%)         MEDIAN SURVIVAL WEEKS (95% CI)   30-DAY SURVIVAL PROBABILITY (95% CI)   HR (95% CI)[\*](#tfn4-pcrt-9-2015-007){ref-type="table-fn"}
  ------------------- ------------- -------------------------------- -------------------------------------- -------------------------------------------------------------
  Group A (\>70%)     173 (77.6%)   17.3 (13.7--19.1)                94% (90--97%)                          1.00 (reference)
  Group B (30--70%)   46 (20.6%)    5.1 (2.4--8.4)                   50% (36--64%)                          2.60 (1.86--3.62)
  Group C (\<30%)     4 (1.8%)      0.6 (0.1--1.0)                   --                                     --

**Notes:**

Model statistics: Likelihood ratio test *χ*^2^~2~ = 52.1; AIC = 1926.5; Harrell *c*-index = 0.611 (standard error 0.013); *D*-index = 2.47; *R*^2^~D~ = 0.593.

###### 

MTPS---median survival and Cox regression model by group (inpatients).

  n (%) n = 421   MTPS (WEEKS)   MEDIAN SURVIVAL WEEKS (95% CI)   HR (95% CI)                 *P*-VALUE (HR = 1)
  --------------- -------------- -------------------------------- --------------------------- --------------------
  148 (35.2%)     \>12           10.9 (8.7--12.3)                 1.00 (reference category)   
  32 (7.6%)       11--12         7.8 (4.6--11.9)                  1.28 (0.87--1.88)           0.21
  62 (14.7%)      7--10          6.3 (3.9--10.7)                  1.65 (1.22--2.23)           0.001
  44 (10.5%)      5--6           4.5 (3.0--6.9)                   1.75 (1.24--2.46)           0.001
  62 (14.7%)      3--4           2.8 (1.6--3.4)                   3.81 (2.79--5.21)           \<0.001
  73 (17.3%)      1--2           0.6 (0.6--0.9)                   13.18 (9.44--18.39)         \<0.001

**Notes:**

Model statistics: Likelihood ratio test *χ*^2^~5~ = 210.3; AIC = 4060.6; Harrell *c*-index = 0.720 (standard error 0.016); *D*-index = 4.38; *R*^2^~D~ = 0.820.

###### 

MTPS---median survival and Cox regression model by group (outpatients).

  n (%) n = 223   MTPS (WEEKS)   MEDIAN SURVIVAL WEEKS (95% CI)   HR (95% CI)                 *P*-VALUE (HR = 1)
  --------------- -------------- -------------------------------- --------------------------- --------------------
  139 (62.3%)     \>12           19.1 (16.4--25.4)                1.00 (reference category)   
  22 (9.9%)       11--12         11.7 (3.6--19.0)                 1.62 (1.03--2.54)           0.04
  31 (13.9%)      7--10          9.3 (5.6--10.1)                  2.44 (1.64--3.63)           \<0.001
  13 (5.8%)       5--6           6.7 (1.1--9.4)                                               
  13 (5.8%)       3--4           1.7 (1.1--6.9)                                               
  5 (2.2%)        1--2           0.7 (0.1--2.6)                                               

**Notes:**

Model statistics: Likelihood ratio test *χ*^2^~5~ = 73.5; AIC = 1911.1; Harrell *c*-index = 0.658 (se 0.017); *D*-index = 3.69; *R*^2^~D~ = 0.765.

###### 

Overestimation factor (MTPS/survival).

               OVERESTIMATION FACTOR (95% CI)   n (EXCLUDES CPS \>12 WEEKS)
  ------------ -------------------------------- -----------------------------
  Inpatient    1.5 (1.4--1.8)                   273
  Outpatient   1.2 (1.0--1.5)                   84

###### 

Spearman correlation inpatients and outpatients.

                    SPEARMAN CORRELATION COEFFICIENT   *P*-VALUE
  ----------------- ---------------------------------- -----------
  **Inpatients**                                       
  PaP               −0.66                              \<0.001
  MTPS              −0.64                              \<0.001
  **Outpatients**                                      
  PaP               −0.57                              \<0.001
  MTPS              −0.53                              \<0.001

**Notes:** Spearman correlation coefficients of \<0.30, 0.30--0.45, 0.45--0.60, and \>0.60 represented none, moderate, substantial, and high correlation, respectively.
